The Cigna Group(CI)Stock Performance & ReturnsNYSE
Returns, drawdowns and benchmark comparison
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
CI | 73.59 B | 11.68x | 6.70% | 2.27% | $23.85 | 16.76% | 0.74x | 2.29% | $315.47 | $239.51 |
CVS | 112.49 B | 23.33x | 7.10% | 1.18% | $3.77 | 6.21% | 0.95x | 3.12% | $110.00 | $68.48 |
LH | 25.30 B | 25.83x | 5.80% | 6.99% | $12.08 | 11.73% | 0.79x | 0.95% | $341.07 | $242.07 |
DGX | 25.06 B | 24.10x | 10.20% | 9.19% | $9.42 | 14.60% | 0.81x | 1.44% | $248.84 | $168.97 |
Peer Valuation & Performance Analysis
Peer group analysis for The Cigna Group (CI) compared to its primary competitors (including CVS, LH, DGX) reveals distinct metrics. CI trades at a valuation discount relative to its competitors, with a P/E ratio of 11.7x versus the peer average of 24.4x (representing a 52% discount). This discount might represent an undervalued entry opportunity or reflect specific risk factors the market is discounting. In terms of growth, CI's revenue growth of 6.7% is consistent with the peer average of 7.7%. Additionally, its net margin of 2.3% is below the peer average of 5.8%, suggesting higher operational costs or lower pricing power relative to peers.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• CI ranks #1 in P/E ratio, #3 in revenue growth, and #3 in profit margins
• Average ranking: #2 - 🎯 Top-tier fundamentals relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-10-07 | $274.88 | $283.13 | $274.76 | $278.51 | 1,632,900 | +1.51% |
| 2026-10-06 | $271.72 | $275.82 | $270.00 | $274.37 | 1,093,400 | +1.14% |
| 2026-10-05 | $270.00 | $273.11 | $266.46 | $271.29 | 1,536,000 | +0.28% |
| 2026-10-02 | $270.03 | $271.40 | $266.00 | $270.53 | 1,914,100 | +0.96% |
| 2026-10-01 | $275.97 | $275.97 | $262.85 | $267.96 | 1,981,000 | -1.42% |
| 2026-09-30 | $274.03 | $278.88 | $263.36 | $271.83 | 3,080,100 | -1.25% |
| 2026-09-29 | $269.97 | $276.61 | $269.01 | $275.26 | 1,978,700 | +1.26% |
| 2026-09-28 | $272.48 | $272.49 | $269.05 | $271.83 | 1,752,800 | -0.07% |
| 2026-09-25 | $266.13 | $273.36 | $265.35 | $272.01 | 1,821,800 | +2.45% |
| 2026-09-24 | $267.90 | $269.33 | $263.76 | $265.50 | 1,611,900 | -1.03% |
| 2026-09-23 | $273.26 | $274.75 | $267.02 | $268.27 | 1,829,700 | -2.00% |
| 2026-09-22 | $276.85 | $278.47 | $272.73 | $273.74 | 1,467,500 | -0.27% |
| 2026-09-21 | $275.91 | $275.91 | $272.62 | $274.47 | 1,394,900 | -0.29% |
| 2026-09-18 | $274.86 | $277.72 | $273.74 | $275.28 | 2,329,600 | -0.26% |
| 2026-09-17 | $280.83 | $281.41 | $275.76 | $276.00 | 1,174,400 | -1.59% |
Explore More Analysis for CI
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.